NAD+ injections: what they are, safety and US cost

Injection or nasal spray: what the choice changes

The injection is given subcutaneously, by you, on the schedule your prescriber sets. The nasal spray is a daily spray and involves no needle. Those are the two things that are certain from what providers publish.

What is not certain is whether the routes deliver differently, and no provider on this page publishes a comparison. Most that sell both charge the same for either, which tells you how they price rather than how the routes perform. Shed is the exception, with its spray priced below its injection. This page does not claim one route is better than the other, because nothing published here supports that claim in either direction.

Seven providers on this page sell the nasal spray. If the spray is what you want to look at, these links go to six of them, each to its NAD+ nasal page where one exists, in the table's order: bmiMD, Embody, Fridays, Luvo Health, Shed and System Labs. We earn a commission on these links, as on the partner links further down.

A third route exists, the in-person IV drip, and it is a different purchase: priced per session rather than per month, at a clinic rather than by post. It is not in the table below, because most US clinics selling NAD+ drips publish no price at all, and a table of two examples would imply a market rate that cannot be sourced.

What NAD+ costs in the US right now

Every figure below was read from the provider's own live page on the date shown, and the page it came from is linked. Nothing here is estimated, interpolated between doses, or taken from a third-party "average cost" round-up. Where a provider publishes no dose, the column says so rather than being filled in. Rows are ordered by route and then alphabetically, never by price. Wellorithm also sells NAD+ online, but it publishes a starting price rather than a supply or dose breakdown, so it is not in the table; our Wellorithm review covers what it does publish.

• bmiMD, injection: Read from the NAD+ Injections card on bmiMD's homepage, which prints it as a "Starting as low as" figure: the lowest of its plan lengths, so a reader who signs up month to month may pay more. The card strikes through a higher figure beside it; bmiMD does not call that a standard price. bmiMD geo-blocks non-US traffic.
• CoreAge Rx, injection: Published as a "Starting at" price per month. The page states upfront pricing with no hidden fees, no membership fees, no long-term contracts, free delivery if prescribed, and that the product is compounded in the USA. It publishes no dose.
• Direct Meds, injection: Published as a "Starting at" price under a money-off NAD+ offer, and read by our daily price collector. The page states no end date for the offer.
• Embody, injection: Embody's NAD+ page shows a first month price and then a monthly price under a pre-Black Friday sale banner worded as money off the first month and every month after. Embody states no standard price and gives no end date for the sale. The prescription and telemedicine visit are stated as included, with free shipping and no membership fee. The page says "Cancel Anytime"; Embody's Refund Policy (updated August 25, 2026) requires a cancellation request to be received at least 72 hours before the next billing date.
• EverPrime, injection: EverPrime's NAD+ injection page prints a STANDARD PRICE row and a MEMBER PRICE row for 1, 3, 6 and 12 month plans. The member figures ($115 for 1 month, $99 on 12 months) need EverPrime's optional membership, $99 a month, on top, billed upfront for the plan length. It names no dose. Read on EverPrime's own page. Our EverPrime links do not open for visitors in the 11 states its affiliate program excludes.
• Fridays, injection: Published as a "Quarterly price" per month, so the figure is the per-month rate on a 3-month plan. Fridays publishes no month-to-month NAD+ price on that page, and also sells NAD+ as an oral liposomal at a higher quarterly price. Fridays' affiliate links do not open in Louisiana.
• Gala, injection: Gala's NAD+ page prints a from price per month for a 28-day supply and a lower per month price on the 3-month plan, charged at checkout, with a full refund if the provider cannot prescribe. It publishes no dose: dosing is confirmed by the provider. Up to a 3-month supply ships per visit, with a quarterly check-in. Compounded NAD+, not FDA approved for this use.
• Hone Health, injection: Hone charges it on top of a monthly membership (Basic or Premium), so the monthly total is higher than the treatment price. Hone lists it for the Basic or Premium tier and does not state whether it is compounded.
• Luvo Health, injection: Luvo bills every 4 weeks rather than monthly, which is 13 billing cycles a year rather than 12. Its product page has shown a discounted first 4 weeks, and its pricing page lists longevity plans from 4 to 24 weeks, with the best value at 24 weeks and no membership fee. It also sells NAD+ as drops.
• Shed, injection: Published as a "Starting at" monthly price for injections, with "Taken 3 times weekly" and "1 month supply". Shed also sells NAD+ as oral tablets and as a nasal spray (see below).
• System Labs, injection: Read from System Labs' own pages. On September 24, 2026 the same page showed a different monthly price with a discounted first month, and System Labs has shown different visitors different prices, so its NAD+ price has changed between our reads.
• Wellorithm, injection: Published as a "Starting at" price for compounded NAD+ injections, with "No Monthly Membership" and "Cancel Anytime" beside it; the lander names no dose and no tier ladder.
• welludr (formerly Wellmedr), injection: Sells compounded NAD+ injections, "500mg-1000mg injections available". We do not re-read this page weekly, so its price and any offer are on welludr's own page rather than here. The page's own wellness claims are not repeated here.
• bmiMD, nasal spray: Read from bmiMD's NAD+ nasal spray page in a browser. The figure is its lowest plan length, and the page strikes through a higher monthly figure beside it. bmiMD blocks our automated reader, so this row is read by hand.
• CoreAge Rx, nasal spray: Listed as "NAD+ Nasal" on CoreAge's NAD+ product page. That page also says its injection has higher potency than its nasal spray.
• Embody, nasal spray: Embody prices its nasal spray identically to its injection, on the same NAD+ page and under the same sale banner, and states no standard price and no end date for the sale. No dose is given for the spray.
• Fridays, nasal spray: Published as a "Quarterly price" per month, the same way as Fridays' injection.
• Luvo Health, nasal spray: Billed every 4 weeks, the same cycle as Luvo's injection. Luvo's pricing page lists its NAD+ injection, drops and nasal spray together, priced by plan length.
• Shed, nasal spray: Published as a "Starting at" monthly price, less than Shed's NAD+ injections.
• System Labs, nasal spray: Read from System Labs' own pages. On September 24, 2026 it showed a different monthly price with a discounted first month.

What NAD+ injections cost over 3, 6 and 12 months

The monthly figure multiplied out, at the lowest and highest ongoing prices in the table. These totals ignore first-month discounts, dose changes and plan-length savings, so treat them as a range, not a quote.

One provider breaks the monthly pattern: Luvo Health bills $199 every 4 weeks, which is 13 billing cycles a year, so a year costs $2,587 rather than $2,388. For GLP-1 prices tracked the same way, every day, see the US GLP-1 price index.

Buying NAD+ online

Thirteen providers we work with that sell NAD+ are listed below alphabetically. That order is not a ranking. We earn a commission if you buy through these links, which changes nothing about the prices above or what we publish about any of them.

PlexusDx, which we have also reviewed, prescribes NAD+ injections through the same online visit as its GLP-1 plans. We have not recorded its NAD+ price, so it is not in the table or the list above; our review covers PlexusDx's NAD+ and longevity peptides. Compounded medicines are not FDA approved.

Compounded medicines: what that word means here

Every NAD+ product on this page is compounded. That means it is prepared against an individual prescription by a compounding pharmacy rather than manufactured as a finished product and reviewed by the FDA. It is a distinct regulatory category: not approved, and not unlawful either.

The practical consequence is that the pharmacy carries more of the responsibility than it would for a branded medicine, which makes it worth asking which one a provider uses. Most of the providers here name no compounding pharmacy on the NAD+ pages we read. That is a gap in what they disclose rather than a finding about what they dispense, and the only way to close it is to ask before you pay.

What the evidence shows, and what it does not

The short answer is that the evidence base for NAD+ injections and nasal sprays is thin. That is a statement about what has been studied, not a finding that NAD+ does or does not work, and each point below is taken from a source listed at the end of this section.

The most recent systematic review. A systematic review published in Aging Research Reviews in 2026 found 113 eligible studies from 2010 to 2025: 33 in humans, 28 of them randomized and 5 not, and 80 in rodents. In the human studies, oral NAD+ precursors (nicotinamide riboside and nicotinamide mononucleotide) consistently raised NAD-related markers in blood and cells. Their effects on functional, metabolic, vascular and other healthspan-related outcomes were mixed, and often absent or limited to particular measures. The authors describe clinical effectiveness for anti-aging or wellness as inconclusive. The precursors were generally well tolerated, but only over weeks to months, so long-term safety was not established by those trials. The review also found no eligible outcomes trial that evaluated NAD+ itself, given intravenously or intramuscularly, for anti-aging or wellness. That means the question has not been tested in such a trial. It does not mean injected NAD+ was tested and found not to work.

Regulatory status. NAD+ is not an FDA-approved drug. A 2021 review prepared for the FDA by the University of Maryland searched FDA's register and found no approved NAD product in the US. The FDA lists NAD, and its reduced form NADH, in Category 1 of the substances nominated for use in compounding: substances it is still evaluating. The FDA says it does not intend to act against a compounder using a Category 1 substance while that evaluation continues, provided the conditions in its guidance are met. That is a policy about enforcement. It is not a finding that the product is safe or effective.

What has been studied in people. The same 2021 review screened the published literature on NAD and found five studies it could include, published between 1961 and 2019, with 154 patients between them. Two were experimental and three descriptive, and the largest enrolled 104 people. They used NAD or NADH mostly by IV drip, with some oral and intramuscular use, for addiction, Parkinson's disease and chronic fatigue syndrome. The review did not grade their quality, and several of the clinicians it interviewed said the clinical evidence for NAD was limited. A 2023 systematic review found ten randomized trials, with 489 participants, but its conclusions concern NADH taken by mouth and NAD+ precursors, which are different products from the injections and sprays on this page.

What the trials measured. The one pilot study we found that tracked NAD+ given directly into a vein followed eleven healthy men, eight of whom received a 750mg infusion over six hours. It measured NAD+ and its breakdown products in blood and urine, and liver enzymes. NAD+ levels in the blood did not change for the first two hours, and no adverse events were observed in the study. It did not measure energy, aging or any other health outcome, and its authors disclose ties to an IV NAD clinic. A 2023 review of oral NAD+ precursors reports that they can raise NAD+ levels, and describes the evidence that this improves physiological function as unclear, with small studies limiting what can be concluded.

What has not been established. We found no controlled trial of self-injected or nasal NAD+ in people among these sources. The FDA-funded review records one patient who used an intranasal NAD spray, alongside IV treatment, in a case report. The most recent intranasal NAD study we found was carried out in mice and in cultured cells. No source here reports an effect of NAD+ injections or sprays on appearance, skin or lifespan. No source here compares injection with nasal spray, which is why this page does not say one route works better.

What is known about side effects. The 2023 systematic review reported side effects in all of the trials it included, most often muscle pain, nervous disorders, fatigue, sleep disturbance and headache, and described none as a serious risk. Clinicians interviewed for the 2021 review said IV NAD has to be given slowly because a fast infusion caused chest tightness or a stomach sensation. None of this was measured for the self-injected or nasal products sold on this page, so their side effect profile is not established in either direction.

Questions to ask before you pay

• Is the advertised price the ongoing one, or a "starting at", first-month, quarterly or long-commitment figure? Most here are one of those.
• What is the month-to-month price if you stop early, and is there a cancellation fee?
• Which compounding pharmacy prepares it, and will they name it before you order?
• What dose does the monthly price cover, and does it change if your prescriber changes the dose?
• Is the product available in your state, and is that confirmed before payment or after?

Frequently asked questions